These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25436807)

  • 21. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
    Ishida H; Ichikawa W; Sasaki Y
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
    Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
    Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
    Weickhardt AJ; Rothman MS; Salian-Mehta S; Kiseljak-Vassiliades K; Oton AB; Doebele RC; Wierman ME; Camidge DR
    Cancer; 2012 Nov; 118(21):5302-9. PubMed ID: 22488744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crizotinib-associated erythema multiforme in a lung cancer patient.
    Sawamura S; Kajihara I; Ichihara A; Fukushima S; Jinnin M; Yamaguchi E; Kohrogi H; Ihn H
    Drug Discov Ther; 2015 Apr; 9(2):142-3. PubMed ID: 25994067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M; De Marinis F; Hirsch FR; Gridelli C
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
    Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
    Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
    Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Widespread renal polycystosis induced by crizotinib.
    Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
    Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of crizotinib in NSCLC patients.
    Hamilton G; Rath B; Burghuber O
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):835-42. PubMed ID: 25732197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC].
    Gao E; Zhao J; Zhuo M; Wang Z; Wang Y; An T; Wu M; Yang X; Zhong J
    Zhongguo Fei Ai Za Zhi; 2016 Mar; 19(3):161-8. PubMed ID: 27009821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cystic Brain Metastases Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung Cancer Patients Receiving Crizotinib.
    Narayanan V; Honce MJ; Mehrotra S; Camidge DR
    Clin Lung Cancer; 2016 Jan; 17(1):85-90. PubMed ID: 26314227
    [No Abstract]   [Full Text] [Related]  

  • 36. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
    Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
    Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analyzing resistance pattern of non-small cell lung cancer to crizotinib using molecular dynamic approaches.
    Kumar A; Ramanathan K
    Indian J Biochem Biophys; 2015 Feb; 52(1):23-8. PubMed ID: 26040108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.